Differences in cardiovascular event rates between atorvastatin and simvastatin among new users: managed-care experience

References

• Shepherd J, Cobbe SM, Ford I,. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-7
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR,. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial. Lancet 2003;361:1149-58
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN,. et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet 2004;364:685-96
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialist (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-78
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD,. et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425-35
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH,. et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-504
   PubMed Web of Science ®Google Scholar
• Pedersen TJ, Faergeman O, Kastelein JJ,. et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized controlled trial. JAMA 2005;294:2437-45
   Google Scholar
• Ridker PM, Rifai N, Rose L,. et al. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J. Med 2002;347: 1557-65
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D,. et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P,. et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005;352:29-38
   PubMed Web of Science ®Google Scholar
• Wiklund O, Mattsson-Hulten L, Hurt-Camejo E,. et al. Effects of simvastatin and atorvastatin on inflammation markers in plasma. J Intern Med 2002;251:338-47
   PubMed Web of Science ®Google Scholar
• van Wissen S. Trip MD. Smilde Tj,. et al. Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy. Atherosclerosis 2002;165:361-6
   PubMed Web of Science ®Google Scholar
• Strandberg TE, Vanhanen H, Tikkanen MJ. Associations between change in C-reactive protein and serum lipids during treatment. Ann Med 2000;32:579-83
   PubMed Web of Science ®Google Scholar
• Joukhadar C, Klein N, Prinz M,. et al. Similar effects of atorvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia. Thromb Haemost 2001;85:47-51
   PubMed Web of Science ®Google Scholar
• Urbich C, Dimmeler S. Risk factors for coronary artery disease, circulating endothelial progenitor cells, and the role of HMG-CoA reductase inhibitors. Kidney Int 2005;67:1672-6
   PubMed Web of Science ®Google Scholar
• Strey CH, Young JM, Molyneux SL,. et al. Endothelium-ameliorating effects of statin therapy and co-enzyme Q10 reductions in chronic heart failure. Atherosclerosis 2005;179:201-6
   PubMed Web of Science ®Google Scholar
• Tousolis D, Antoniades C, Bosinakou E,. et al. Effects of atorvastatin on reactive hyperemia and inflammatory process in patients with congestive heart failure. Atherosclerosis 2005; 178:359-63
   PubMed Web of Science ®Google Scholar
• de Lemos JA, Blazing MA, Wiviott SD,. et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z trial. JAMA 2004; 292:1307-16
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Olson AG, Ezekowitz MD,. et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized clinical trial. JAMA 2001;285:1711-18
   PubMed Web of Science ®Google Scholar
• Zhou Z, Rahme E, Abrahamowicz M,. et al. Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ 2005; 172:1187-94
   PubMed Web of Science ®Google Scholar
• Dieleman JP, van Wyk JT, van Wijk MAM,. et al. Differences between statins on clinical endpoints: a population-based cohort study. Curr Med Res Opin 2005;21:1461-8
   PubMed Web of Science ®Google Scholar
• Foody JM, Joyce AT, Rudolph AE,. et al. Cardiovascular outcomes among patients newly initiating atorvastatin or simvastatin: a large database analysis of managed care plans in the U.S. Clin Ther 2008;30:195-205
   PubMed Web of Science ®Google Scholar
• Benner JS, Glynn RJ, Mogun H,. et al. Long-term persistence in use of statin therapy by elderly patients. JAMA 2002;288: 455-61
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL,. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
   PubMedGoogle Scholar
• Meenan RT, Goodman MJ, Fishman PA,. et al. Using risk-adjustment models to identify high-cost risks. Med Care 2003;41: 1301-12
   PubMed Web of Science ®Google Scholar
• Stata Statistical Software: Release 9. College Station, TX: Statacorp LP
   Google Scholar
• http://www.drugdigest.org/DD/Comparison/NewComparison/ 0,10621,37-15,00.html
   Google Scholar
• Wiviott SD, de Lemos JA. Cannon CP,. et al. A tale of two trials: a comparison of the post-acute coronary syndrome lipid-lowering trials A to Z and PROVE-IT TIMI 22. Circulation 2006; 113:1406-14
   PubMed Web of Science ®Google Scholar
• Phillips B, Roberts C, Rudolph AE,. et al. Switching statins: the impact on patient outcomes. Br J Cardiol 2007;14:280-5
   Google Scholar
• Zhou Z, Rahme E, Pilote L. Are statins created equal? Evidence from randomized clinical trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Am Heart J 2006;151:273-81
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP,. et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: a randomized clinical trial. JAMA 2005;294:2437-45
   PubMed Web of Science ®Google Scholar
• Butler R, Wainwright J. Cholesterol lowering in patients with CHD and metabolic syndrome: Correspondence. Lancet 2007; 369:27
   PubMed Web of Science ®Google Scholar